Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics sets up $200 million at-the-market stock sale program with Jefferies

Neutral Impact 3 of 5 financing Written later

Avalo Therapeutics entered an at-the-market sales agreement with Jefferies LLC that lets it sell up to $200 million of common stock over time at its discretion, with a commission of up to 3.0% of gross proceeds. The same day, the company ended its prior at-the-market agreement with TD Cowen, effective immediately, so new share sales can only occur under the Jefferies arrangement. New share sales would add to the outstanding shares and could dilute existing shareholders.

Key points

  • Jefferies sales agreement covers up to $200,000,000 in aggregate offering price under a prospectus supplement dated November 5, 2026.
  • Company pays Jefferies a commission of up to 3.0% of gross proceeds from any shares sold.
  • The company is not obligated to sell any shares, and it may suspend or terminate the offering.
  • TD Cowen sales agreement, dated June 5, 2025, was terminated effective November 5, 2026.

The filing

CompanyAvalo Therapeutics, Inc. (AVTX)
Form8-K, current report
Filed with the SECNov 5, 2026, 8:07 AM ET
Accession number0001104659-26-123079

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.